0001209191-20-029918.txt : 20200515
0001209191-20-029918.hdr.sgml : 20200515
20200515210242
ACCESSION NUMBER: 0001209191-20-029918
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200515
FILED AS OF DATE: 20200515
DATE AS OF CHANGE: 20200515
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Barry Richard
CENTRAL INDEX KEY: 0001562371
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 20887538
MAIL ADDRESS:
STREET 1: 285 MARGALITA DRIVE
CITY: SAN RAFAEL
STATE: CA
ZIP: 94901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-15
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001562371
Barry Richard
215 FIRST STREET, SUITE 415
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2020-05-15
4
S
0
25327
141.12
D
3163813
D
Common Stock
2020-05-15
4
S
0
4673
142.05
D
3159140
D
The shares were sold in transactions at prices ranging from $140.60 to $141.54, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The shares were sold in transactions at prices ranging from $142.00 to $142.30, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
/s/ David Tyronne Howton, as Attorney-in-Fact for Richard Barry
2020-05-15